fty-720p and sphingosine-1-phosphate

fty-720p has been researched along with sphingosine-1-phosphate* in 3 studies

Other Studies

3 other study(ies) available for fty-720p and sphingosine-1-phosphate

ArticleYear
Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based Series.
    Journal of medicinal chemistry, 2016, Mar-24, Volume: 59, Issue:6

    Sphingosine 1-phosphate (S1P) is the endogenous ligand for the sphingosine 1-phosphate receptors (S1P1-5) and evokes a variety of cellular responses through their stimulation. The interaction of S1P with the S1P receptors plays a fundamental physiological role in a number of processes including vascular development and stabilization, lymphocyte migration, and proliferation. Agonism of S1P1, in particular, has been shown to play a significant role in lymphocyte trafficking from the thymus and secondary lymphoid organs, resulting in immunosuppression. This article will detail the discovery and SAR of a potent and selective series of isoxazole based full agonists of S1P1. Isoxazole 6d demonstrated impressive efficacy when administered orally in a rat model of arthritis and in a mouse experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis.

    Topics: Animals; Arthritis, Experimental; Cell Movement; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; Drug Discovery; Encephalomyelitis, Autoimmune, Experimental; Humans; Immunosuppressive Agents; Isoxazoles; Lymphatic System; Lymphocytes; Lysophospholipids; Mice; Mice, Inbred C57BL; Rats; Rats, Inbred Lew; Sphingosine; Structure-Activity Relationship; Thymus Gland

2016
Synthesis of 4(5)-phenylimidazole-based analogues of sphingosine-1-phosphate and FTY720: discovery of potent S1P1 receptor agonists.
    Bioorganic & medicinal chemistry letters, 2005, Aug-01, Volume: 15, Issue:15

    The novel immunosuppressant FTY720 has been demonstrated to elicit immunomodulating effects via interaction with the G-protein coupled receptor S1P(1). FTY720 induced agonism at the S1P(3) receptor, however, has been shown to result in mild bradycardia, a minor side-effect of initial FTY720 therapy. This report describes the synthesis of several potent 4(5)-phenylimidazole-based S1P(1) receptor agonists that are accompanied by poor agonist activity at S1P(3). For instance, compound 20 displayed an EC(50)=4.7+/-1.3 nM at the S1P(1) receptor and EC(50)=780+/-1.3 nM at the S1P(3) receptor using a [gamma-(35)S]GTP-binding assay as compared to phospho-FTY720 (S1P(1): EC(50)=1.3+/-1.3nM, S1P(3): EC(50)=2.0+/-2.4 nM).

    Topics: Animals; Benzimidazoles; Binding Sites; Bradycardia; CHO Cells; Cricetinae; Fingolimod Hydrochloride; Immunosuppressive Agents; Lethal Dose 50; Lysophospholipids; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Structure-Activity Relationship

2005
Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes.
    The Journal of pharmacology and experimental therapeutics, 2004, Volume: 309, Issue:2

    Sphingosine 1-phosphate (S1P) is a bioactive lysolipid with pleiotropic functions mediated through a family of G protein-coupled receptors, S1P(1,2,3,4,5). Physiological effects of S1P receptor agonists include regulation of cardiovascular function and immunosuppression via redistribution of lymphocytes from blood to secondary lymphoid organs. The phosphorylated metabolite of the immunosuppressant agent FTY720 (2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol) and other phosphonate analogs with differential receptor selectivity were investigated. No significant species differences in compound potency or rank order of activity on receptors cloned from human, murine, and rat sources were observed. All synthetic analogs were high-affinity agonists on S1P(1), with IC(50) values for ligand binding between 0.3 and 14 nM. The correlation between S1P(1) receptor activation and the ED(50) for lymphocyte reduction was highly significant (p < 0.001) and lower for the other receptors. In contrast to S1P(1)-mediated effects on lymphocyte recirculation, three lines of evidence link S1P(3) receptor activity with acute toxicity and cardiovascular regulation: compound potency on S1P(3) correlated with toxicity and bradycardia; the shift in potency of phosphorylated-FTY720 for inducing lymphopenia versus bradycardia and hypertension was consistent with affinity for S1P(1) relative to S1P(3); and toxicity, bradycardia, and hypertension were absent in S1P(3)(-/-) mice. Blood pressure effects of agonists in anesthetized rats were complex, whereas hypertension was the predominant effect in conscious rats and mice. Immunolocalization of S1P(3) in rodent heart revealed abundant expression on myocytes and perivascular smooth muscle cells consistent with regulation of bradycardia and hypertension, whereas S1P(1) expression was restricted to the vascular endothelium.

    Topics: Anesthesia; Animals; CHO Cells; Cricetinae; Fingolimod Hydrochloride; Humans; Lysophospholipids; Male; Mice; Myocardium; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Sphingosine

2004